Last reviewed · How we verify
Meilax (ETHYL LOFLAZEPATE)
Meilax (generic name: ETHYL LOFLAZEPATE) is a ethyl loflazepate drug. It is currently in Phase 2 development for Anxiety, Depressive disorder.
Meilax works by enhancing the activity of a neurotransmitter called gamma-aminobutyric acid (GABA), which helps to calm the brain and reduce anxiety.
Meilax, also known as ethyl loflazepate, is a small molecule drug in the benzodiazepine class. It is used to treat anxiety and depressive disorders. The commercial status of Meilax is currently unknown, and it is not clear if it is patented or available as a generic medication. Further research is needed to determine its key safety considerations and pharmacokinetic properties.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ETHYL LOFLAZEPATE |
|---|---|
| Drug class | ethyl loflazepate |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain is like a busy city with lots of people talking and moving around. GABA is like a traffic cop that helps to slow down the traffic and keep everything calm. Meilax helps the traffic cop to do its job more effectively, which can help to reduce feelings of anxiety and stress.
Approved indications
- Anxiety
- Depressive disorder
Common side effects
- Altered state of consciousness
- Parkinsonism
- Tongue oedema
- Suicide attempt
- Neuroleptic malignant syndrome
- Irritability
- Mallory-Weiss syndrome
- Rhabdomyolysis
- Overdose
- Hepatic function abnormal
- Pressure of speech
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meilax CI brief — competitive landscape report
- Meilax updates RSS · CI watch RSS
Frequently asked questions about Meilax
What is Meilax?
How does Meilax work?
What is Meilax used for?
What is the generic name of Meilax?
What drug class is Meilax in?
What development phase is Meilax in?
What are the side effects of Meilax?
Related
- Drug class: All ethyl loflazepate drugs
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Anxiety
- Indication: Drugs for Depressive disorder
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing